Literature DB >> 11776311

The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.

B Verbruggen1, A Giles, J Samis, K Verbeek, E Mensink, I Novákovà.   

Abstract

We have investigated the influence of the type of factor VIII deficient plasma used on the assay results of the Nijmegen modification of the Bethesda method for factor VIII inhibitors. Immuno depleted factor VIII deficient plasmas, lacking besides factor VIII also von Willebrand factor, gave decreased inhibitor titres compared to assay results with factor VIII deficient plasmas containing von Willebrand factor suggesting the need of the latter in the test system for the stability of factor VIII:C. Moreover the performance of the assay with immuno depleted plasma was contaminated in a certain type of this plasma by the presence of a factor VIII:C inhibitor. Chemically depleted factor VIII deficient plasma appeared to give falsely elevated titres when used in combination with other types of deficient plasmas as substrate plasma in the factor VIII:C assay due to the presence of activated factor Va in the preparation. Suggestions are described with respect to the observed limitations in order to obtain reliable results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11776311

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.

Authors:  Der-Shan Sun; Po-Chien Lee; Jyh-Hwa Kau; Yung-Luen Shih; Hsin-Hsien Huang; Chen-Ru Li; Chin-Cheng Lee; Yu-Ping Wu; Kuo-Ching Chen; Hsin-Hou Chang
Journal:  Virulence       Date:  2015-04-23       Impact factor: 5.882

2.  Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.

Authors:  C H Miller; A B Payne; J Driggers; D Ellingsen; B Boylan; C J Bean
Journal:  Haemophilia       Date:  2018-03-24       Impact factor: 4.287

Review 3.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

4.  Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.

Authors:  Q Shi; E L Kuether; J A Schroeder; C L Perry; S A Fahs; J Cox Gill; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

Review 5.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.